atai Life Sciences shares plummet as r-ketamine candidate fails to meet primary endpoint in Phase 2a trialProactive Investors • 01/06/23
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant DepressionGlobeNewsWire • 01/06/23
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101GlobeNewsWire • 12/23/22
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with SchizophreniaGlobeNewsWire • 12/19/22
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General HospitalGlobeNewsWire • 12/16/22
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business OfficerGlobeNewsWire • 11/29/22
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 11/10/22
atai Life Sciences to Participate in November Investor Events & Healthcare ConferencesGlobeNewsWire • 11/01/22
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant DepressionGlobeNewsWire • 10/25/22
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery TechnologyGlobeNewsWire • 10/18/22
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUDGlobeNewsWire • 10/12/22
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMTGlobeNewsWire • 10/05/22
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D DayGlobeNewsWire • 10/04/22